Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Coronavirus (COVID-19) / Coronavirus Research

Coronavirus Research at URMC

New Clinical Trial

The University of Rochester Medical Center (URMC) is participating in a NIH-sponsored clinical trial to evaluate the safety and efficacy of the investigational antiviral drug remdesivir in hospitalized adults diagnosed with COVID-19.

  • We’re experts in the field of infectious disease and infection control. Using our expertise, we’ve put procedures in place across our UR Medicine health system to evaluate and care for patients in the event of an outbreak in our area. We’ve also taken the necessary steps to ensure the safety of faculty, staff, students, visitors, and volunteers.
  • URMC scientists and clinicians are at the forefront of the national response to the COVID-19 pandemic. URMC researchers are working with federal, state and local agencies to understand how COVID-19 spreads through populations, how the body responds to the infection, and who is vulnerable to harm from the disease. URMC researchers are also racing to develop new therapies to help patients recover from COVID-19 and, ultimately, a new vaccine that will prevent the disease. This research is spread across many labs and centers across the University.
  • URMC is one of five NIH Centers of Excellence in Influenza Research and Surveillance. Our investigators are part of the Global Virus Network which is helping to coordinate the worldwide response to the COVID-19 threat. Our scientists are conducting studies that will help determine how many people have been affected by the virus, including those who may not have shown symptoms. This will support efforts to learn more about how the virus spreads and how to better protect communities.
  • In January 2020, URMC was awarded $4.3 million by the National Institutes of Health (NIH) to establish the UR Vaccine Trials and Evaluation Unit (VTEU), which conducts clinical trials of vaccines, treatments, and diagnostics for known and emergent infectious threats. URMC is one of only nine VTEU sites in the U.S. In March, the VTEU launched a clinical trial to test a potential new treatment for COVID-19.
  • The URMC New York Influenza Center of Excellence (NYICE) is a multidisciplinary, multi-institutional, center that emphasizes basic and clinical research on human influenza surveillance, pathogenesis and host responses to infection and vaccination. NYICE researchers are investigating how the immune system responds to COVID-19 to better understand how long individuals are immune from re-infection once they have recovered and the boost to immunity provided by a potential COVID-19 vaccine.
  • The New York State Emerging Infections Program (EIP) is part of the federal Centers for Disease Control & Prevention's national effort to provide population-based communicable disease data to identify disease patterns, evaluate vaccine programs, and to identify at-risk populations. The URMC EIP will be performing laboratory and population-based surveillance for COVID-19 as part of a multi-site national study. The group will collect a variety of demographic and clinical data that will be reported to the Centers for Disease Control & Prevention and the Monroe County Department of Public Health.
  • We will be launching new clinical trials. We’re opening early clinical trials to test new preventive vaccines, antivirals, and mechanical treatments, which means our own patients may have early access to new therapies.​ Sign up for our research registry to be alerted of new opportunities to participate in health research (you can now select COVID-19/Coronavirus as an area of research interest). If you are currently participating in one of our clinical studies that was paused due to the COVID-19 pandemic, you can learn more on our FAQ page.

COVID-19 Guidance for Researchers

The University of Rochester (UR) and Medical Center (URMC) are closely monitoring the evolving COVID-19 situation and developing policies to keep students, faculty, and staff safe. Some of those policies will impact research operations and require specific guidance to help us maintain operations while keeping our research community safe. Visit the COVID-19 Guidance for Researchers site for guidance on Human Subjects, Laboratory and Animal Research as well as COVID-19-related research funding opportunities.

This is a rapidly changing situation, so please check back frequently. We will be updating and adding information as it becomes available. If you have a questions regarding COVID-19 and research (policies, opportunities for collaboration, etc.), please direct them to the UR CTSI’s Research Help Desk: